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ABSTRACT
Adult-type granulosa cell tumor is a clinically and molecularly unique subtype of ovarian cancer.
These tumors originate from the sex cord stromal cells of the ovary and represent 3–5% of all
ovarian cancers. The majority of adult-type granulosa cell tumors are diagnosed at an early stage
with an indolent prognosis. Surgery is the cornerstone for the treatment of both primary and
relapsed tumor, while chemotherapy is applied only for advanced or non-resectable cases.
Tumor stage is the only factor consistently associated with prognosis. However, every third of
the patients relapse, typically in 4–7 years from diagnosis, leading to death in 50% of these
patients. Anti-M€ullerian Hormone and inhibin B are currently the most accurate circulating bio-
markers. Adult-type granulosa cell tumors are molecularly characterized by a pathognomonic
somatic missense point mutation 402C->G (C134W) in the transcription factor FOXL2. The FOXL2
402C->G mutation leads to increased proliferation and survival of granulosa cells, and promotes
hormonal changes. Histological diagnosis of adult-type granulosa cell tumor is challenging,
therefore testing for the FOXL2 mutation is crucial for differential diagnosis. Large international
collaborations utilizing molecularly defined cohorts are essential to improve and validate new
treatment strategies for patients with high-risk or relapsed adult-type granulosa cell tumor.
KEY MESSAGES:
 Adult-type granulosa cell tumor is a unique ovarian cancer with an indolent, albeit unpredict-
able disease course.
 Adult-type granulosa cell tumors harbor a pathognomonic somatic missense mutation in tran-
scription factor FOXL2.
 The key challenges in the treatment of patients with adult-type granulosa cell tumor lie in
the identification and management of patients with high-risk or relapsed disease.
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Introduction
Granulosa cell tumour (GCT) of the ovary is a rare sub-
type of ovarian cancer originating from the sex-cord
stromal component of the ovary (1). The incidence of
GCTs is 0.6–0.8/100,000, and it accounts for 3–5% of
all ovarian malignancies (2). GCTs present with two
clinically and molecularly distinct subtypes; the juven-
ile and the adult type (1). Adult-type GCT (AGCT) is
the more common, whereas the juvenile comprises
only 5% of all GCTs. Juvenile GCT is generally diag-
nosed at early stage in children and adolescents, and
presents with a favorable prognosis, although at
advanced stages the clinical course may be more
aggressive (3). Although extremely uncommon, the
juvenile type can be found in adults and the adult
type in children. AGCTs are usually diagnosed in peri-
menopausal women between ages 50 and 54,
although it can occur throughout the adult woman’s
lifespan. AGCT is a unique subtype of ovarian cancer
with distinct clinical and molecular features. This
review focuses on the current view on the pathogen-
esis and treatment of AGCTs of the ovary.
Presentation and diagnosis
Clinical presentation
AGCTs are clinically distinct ovarian cancers due to
their prominent hormonal activity and production of
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estrogen and inhibins (1). The most common present-
ing symptoms are abnormal vaginal bleeding (45%),
and abdominal pain or bloating (10–20%) (4). In pre-
menopausal patients, AGCT typically cause irregular
bleeding, amenorrhea and more infrequently infertility
(4). In postmenopausal patients, abnormal vaginal
bleeding associated with a unilateral ovarian mass is
the most common clinical presentation. Ascites is
rarely present in the primary diagnosis. In 8–15% of
the cases, the tumor presents with a spontaneous
rupture manifesting as acute abdominal pain and
hemoperitoneum (4,5). In ultrasonography, AGCT char-
acteristically presents with a cystic to solid ovarian
mass with high vasculature (6). Typically, these
patients also have an abnormally thick endometrium,
pathological examination may reveal endometrial
hyperplasia in 26–38% and synchronous endometrial
cancer is diagnosed in 6–7% of the patients (4,7).
Prognosis
Outcomes
Due to the slow growth and distinguishable hormo-
nal symptoms, AGCTs are generally diagnosed at an
early stage. The majority (50–80%) are diagnosed at
stage Ia (4,5,8,9), in which the tumor is completely
inside the ovarian capsule, and no tumor cells are
found outside the ovary (10). The second most com-
mon (30%) is stage Ic, in which tumor cells infiltrate
through the ovarian capsule, or the capsule is rup-
tured either spontaneously or due to iatrogenic rea-
sons. Generally, AGCTs have a remarkably indolent
behavior compared to other ovarian malignancies.
However, the reported outcomes have significantly
varied between cohorts; the reported 5-year overall
survival rates between 61% and 95% and disease-spe-
cific survival rates between 67% and 99% have been
reported (Table 1). Likewise, the recurrence rates may
vary between 6% and 48%. However, in a validated
large cohort, patients have excellent outcomes, with
the overall survival comparable to a general age-
matched population; the 5- and 10-year overall sur-
vival rates are 98% and 84%, respectively (11). In
addition, in advanced stage (III–IV), molecularly
defined AGCTs are extremely uncommon.
Even though most early stage AGCT patients experi-
ence an excellent outcome, every third patient will
eventually develop a tumor relapse, and this will lead
to death in 50–80% of the relapsed patients (4,11,12).
Thus, a unique challenge in the treatment of AGCT
patients lies in the long latency to disease relapse; the
typical time to relapse varies between 4 and 8 years
(4,8,13) the median being 7.2 years in a histologically
and molecularly defined large AGCT cohorts (11).
AGCT may, however relapse even after 30–40 years
from diagnosis (14), warranting for life-long surveil-
lance of especially in the high-risk patients. The cellu-
lar mechanisms of latency and late relapse have not
been established in AGCTs, however they may include
mechanisms of tumor dormancy similarly to those
reported in breast cancer (15).
Prognostic factors
Multiple clinical and histological prognostic factors
have been investigated for their role in AGCT prognos-
tics, however the results have been inconclusive and
varied significantly between cohorts. Tumor stage is
the only consistent factor that has been linked to
tumor relapse and survival (4,8,16). Among the stage I
patients, those with tumor penetrating the ovarian
capsule or tumor rupture (stage Ic) have a significantly
increased risk of disease relapse (9,17). Consistently,
rupture of the tumor capsule has been implicated as
an adverse prognostic indicator, also in stage I AGCTs
(17–19). Interestingly, in a recent study of verified
AGCTs, there was no difference in the risk of relapse
between surgically or spontaneously ruptured tumors
(17). The identification of risk factors among stage I
patients is the clinically most important determinant
since stage I patients form the majority of AGCT
patients. Thus, future clinical and scientific efforts need
to be concentrated on how to identify and manage
early-stage AGCT patients at increased risk of relapse.
In addition, some studies have reported postoperative
residual tumor (19) as well as large tumor size as an
adverse prognostic factors (8,18). However, the adjust-
ment of tumor stage is not clearly defined in these
studies, and some studies show inconsistent results
(12,13,20). Further, it is not clear whether patient age
at diagnosis affects the prognosis (4,20), whereas par-
ity and reproductive status do not seem to influence
outcome of AGCTs (4).
Regarding histopathological prognostic factors, the
different histological subtypes have not been associ-
ated with prognosis (19), whereas high mitotic activity
and nuclear atypia have been shown to predict worse
prognosis (21,22). Multiple histological prognostic fac-
tors, e.g. Ki67, p53, members of the epidermal growth
factor receptor (EGFR) family, and transcription factor
GATA4 have been evaluated (22,23), but their clinical
applicability remains unclear. The potential histopatho-
logical prognostic factors have not yet been validated
in independent validated cohorts limiting their use in
clinical decision-making.
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Accurate diagnosis
AGCTs are relatively uncommon and can show histo-
morphological patterns similar to a variety of other
unrelated tumors, therefore an unequivocal diagnosis
of AGCT can be challenging. Consequently, in histor-
ical series false positive diagnosis rates of up to 36%
have been recorded (4,12). A single somatic missense
mutation (C134W) in the gene encoding for transcrip-
tion factor FOXL2 has been found to be present in
95% of AGCTs, making it a pathognomonic defining
feature (24), and this finding has been verified in mul-
tiple independent cohorts (11,25–29). The mutation is
specific to AGCT, and is not present in any other
tumors including juvenile GCTs (30,31). Thus, the
FOXL2 mutation has been shown to be essential in the
differential diagnosis of AGCTs (32,33). In conjunction
with expert pathological morphologic assessment,
FOXL2 mutation testing, and the appropriate immuno-
histochemical markers is strongly recommended for
current clinical pathological diagnoses (11,32,34). As
direct Sanger sequencing for the FOXL2 mutation,
especially from formalin the fixed paraffin-embedded
tissue can often result in false negative results (32),
the mutational analysis is recommended to be per-
formed using an allelic discrimination assay or other
sensitive methods (11). An accurate diagnosis is crucial
since misdiagnosis can have profound effects on
patient prognosis; the majority of misdiagnosed cases
have been shown to be more aggressive tumors with
significantly worse outcomes (11). Conversely, molecu-
larly defined AGCTs present with a consistently indo-
lent course with slow progression. Incorporating FOXL2
mutation testing into routine pathological assessment
will aid in moving towards a universal and reprodu-
cible correct diagnoses, and create uncontaminated
cohorts for clinical trials.
Due to recent technical developments, the specific
FOXL2 mutation offers an intriguing opportunity for
non-invasive diagnostics from cell-free circulating
tumor DNA (ctDNA) (35). The advances in digital drop-
let PCR technology has allowed for the development
of a sensitive and specific technique to identify low-
frequency FOXL2 ctDNA mutations in a high back-
ground of wild-type DNA (36). According to this recent
proof of principle study, the FOXL2 mutation was
found in the ctDNA from 35% of patients with primary
AGCT, and 19% of patients with relapsed disease.
Consistent, with previous findings (37), the mutation
was more likely found from the plasma of patients
with larger tumors (36). The question arises whether
ctDNA FOXL2 mutation positivity at primary diagnosis
or during follow-up can predict tumor recurrence,
similar to findings in patients with early-stage breast
cancer (37). However, the clinical utility of ctDNA
FOXL2 mutation in AGCT patients will need to be fur-
ther developed and validated in future clinical trials.
Pathogenesis
Molecular pathogenesis
The transcription factor FOXL2 plays a crucial role in
regulating follicular development in the normal ovary
(38), and it is crucial for granulosa cell differentiation
(39). In AGCTs, the mechanism how the FOXL2 muta-
tion causes tumor formation remains an area of active
investigation. At the molecular level, the C134W muta-
tion is not linked to alterations in the protein structure
(40), but instead it causes a change in the posttransla-
tional modification (ubiquitination) leading to impaired
interactions of FOXL2 with other transcription factors
(41). The current evidence suggests that a key event in
AGCT pathogenesis is a failure of the mutant FOXL2 to
form specific protein–protein interactions leading to
subtle changes in the transcription of target genes (42).
This creates a transcriptomics profile portraying the typ-
ical hallmarks of cancer (43). The impact of the FOXL2
mutation in AGCT pathogenesis is depicted in Figure 1.
Interplay of transcription factors
A key result of the FOXL2 mutation seems to be in the
dysregulation of cell cycle and apoptosis. Wild-type
FOXL2 negatively regulates cell-cycle progression (44)
and promotes apoptosis (45). In contrast, the FOXL2
C134W mutant upregulates genes involved in cell-
cycle progression and downregulates genes involved
in apoptosis (43,45,46). Mutant FOXL2 has been linked
to altered interactions with the SMAD transcription
factors of the TGB-b/BMP signaling pathway (40,47),
which are essential intracellular mediators in normal
granulosa cells. A key effect of FOXL2 appears to be
mediated through its interaction with SMAD3 (48,49).
In normal granulosa cells, SMAD3 mediates activin A
and transforming growth factor-b (TGF-b) signals regu-
lating the expression of cyclin D2 and gonadal genes
such as inhibin (50). In AGCTs, SMAD3 has been shown
to differentially regulate a gonandotrophin releasing
hormone activating promoter together with mutant
FOXL2 as compared to wild-type FOXL2 (40).
Furthermore, mutant FOXL2 has been shown to inhibit
the induction of anti-proliferative follistatin, leading to
increased cell proliferation and tumor formation (51).
In addition to SMAD3, FOXL2 interacts with multiple
transcription partners in AGCTs. GATA4 is a zinc finger
438 A. F€ARKKIL€A ET AL.
transcription factor that plays a crucial role in ovarian
follicular development granulosa cells being the major
site of GATA4 expression in the ovary (52). In granu-
losa cells, follicle stimulating hormone (FSH) and TGF-b
upregulate the expression of GATA4 (53), and GATA4
subsequently acts to moderate many factors crucial for
granulosa cell proliferation and function (53), including
AMH (54), aromatase (55), and a-inhibin (54). The
majority of AGCTs express GATA4 at levels comparable
to normal preovulatory granulosa cells (52), and high
GATA4 expression in these tumors predicts both
increased risk of recurrence and shorter disease spe-
cific survival (22). Further, GATA4 protein expression
correlates with the expressions of the intrinsic apop-
totic pathway inhibitor Bcl2, and proproliferative cyclin
D2 (56), and overexpression of GATA4 protects AGCT
cells from apoptosis (57). GATA4 has also been shown
to physically interact with SMAD3 and FOXL2 to
modulate gene expression, cell viability, and apoptosis
in AGCTs (58). Taken together, these data suggest that
GATA4 acts as an anti-apoptotic factor promoting
tumor growth in AGCTs. Although FOXL2 and GATA4
play pivotal roles in AGCT tumorigenesis, they are diffi-
cult to target when developing new treatment strat-
egies for advanced AGCT. Therefore, future therapeutic
agents may need to be targeted at the downstream
effects of these transcription factors, most importantly
factors related to apoptosis, proliferation and hormo-
nal regulation.
Hormonal factors
AGCTs are derived from the rapidly dividing granulosa
cells of small preantral follicles, and express the recep-
tors for several hormonal regulators (59). Wild-type
FOXL2 regulates the expression of multiple hormonal
factors such as SF1, CYP19A1, HSD17B1, ESR1, ALK6
(BMPR1beta), SOX9, and StAR (60,61). Wild-type FOXL2
causes the repression of StAR and an incresase in
CYP19A1 maintaining the female phenotype in granu-
losa cells (39). In granulosa cells, follicle-stimulating
hormone (FSH) is an integral regulator of proliferation
and hormonal function. FSH binds to its transmem-
brane receptor, activates transcription via cAMP-
mediated pathways resulting in increased expression
of, e.g. CYP19A1 (aromatase) and cyclin D2, and pro-
moting cell proliferation. AGCTs are known to express
functional FSH receptors activating FSH signaling (62).
At diagnosis, AGCT patients typically present with low-
circulating FSH levels due to inhibitory feed-back
mechanisms of tumor-produced estradiol and inhibins.
The pathogenetic role of FSH in AGCTs remains incon-
clusive, and several studies have failed to identify
genetic alterations in FSH receptor, or other G-protein
coupled receptors (59,62). In addition to FSH, FOXL2
regulates aromatase expression, and mutant FOXL2
has been shown to directly activate the aromatase
promoter (63). AGCT cells have abundant aromatase
activity (64), and consequently AGCTs produce estro-
gens (65). AGCTs also express high levels of estrogen
receptors; nuclear estrogen receptor (ER) a expression
has been reported in a minority (20%) of AGTS,
whereas virtually all AGCTs are ERb positive (66). In
addition, AGCTs have been reported to express a
newly characterized, membrane-bound G-protein
linked estrogen receptor (GPER1 or GPR30) (67). The
para/autocrine actions of tumor-secreted estradiol are
unknown, and evidence supporting the assumption
that endogenous estradiol promotes tumor growth is
lacking. By contrast, it has been shown that estradiol
binding to nuclear estrogen receptors (ERa or ERb)
does not activate transcription in AGCT cells due to
repression by the NFkB pathway via SMAD3 (68,69). In
addition, recent evidence suggests that estradiol may
in fact decrease metastasis and invasion of AGCT cells
via activation of GPER1 (67). The effects of tumor-pro-
duced and exogenous estradiol, such as hormone
replacement therapy, need to be further explored. This
is also vital in order to interrogate the mechanism of
action of the currently applicable hormonal treat-
ments, such as aromatase inhibitors. A recent single-
institute retrospective study reported only modest
responses with hormone therapy (objective response
rate 18%), although a significant proportion (60%) of
the patients remained with stable disease (70). Future
studies will hopefully shed more light into whether
the hormonal pathways can also be exploited to
prevent relapse in high-risk patients similar to other
hormone-dependent cancers.
TGF-b family members
Anti-m€ullerian hormone (AMH), also referred to as
M€ullerian inhibiting substance, belongs to the TGF-
b/bone morphogenic protein family of signaling mole-
cules. AMH is a key regulator of follicular development
in the ovary (71). In granulosa cells, AMH expression is
regulated by steroidogenic factor-1, GATA4 (72), and
FSH (73), and the granulosa cell-produced AMH further
regulates follicular development in the ovary (71).
AMH exerts its effects by binding to a heterodimeric
cell surface receptor complex consisting of type I and
type II (AMHRII) receptors, that activate downstream
SMAD 1, 5, and 8. In the adult female, AMHRII is
expressed in granulosa cells and at low levels in ovar-
ian stroma and endometrium (74). In gynecological
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cancers, AMRII is highly expressed in cancers of the
ovary, endometrium (74). AGCTs are known to express
AMH, and AMH has been shown to act as a sensitive
and specific circulating tumor marker for AGCT (75).
Interestingly, several mouse models suggest that
imbalances in the TGF-b/bone morphogenic pathway,
and specifically the overactivity of TGF-b-type signaling
and SMAD2/3 contributes to GCT formation (76).
Further, recombinant human AMH was shown to acti-
vate SMAD1/5 signaling and induce apoptosis in AGCT
cells (77), indicating that AMH pathway acts as a
growth inhibitor also in AGCTs. AMH targeting agents
may thus present as an interesting therapeutic option
for AGCTs. Moreover, receptors that are highly and
specifically expressed in cancers, such as AMHRII, pre-
sent as rational targets for the development of novel
therapies (78).
Tumor angiogenesis
Tumor growth relies on mechanisms of angiogenesis,
the growth of new blood vessels from pre-existing vas-
culature in order to supply oxygen and nutrients. This
angiogenic process in tumors is mainly driven by
Vascular Endothelial Growth Factor-A (VEGF). In grow-
ing tumors, hypoxia is the main stimulator of VEGF
expression through hypoxia-inducible factor 1a (HIF-
1a), but also many cytokines and growth factors, such
as TGF-a and TGF-b stimulate VEGF expression (79).
VEGF is expressed in the majority of solid tumors as
well as in some hematological malignancies, and its
expression correlates with disease progression and sur-
vival (79). AGCTs are typically highly vascularized and
express VEGF and its receptors (80). VEGF signaling
seems to be required for the survival of AGCT cells
in vitro (80) and tumor progression in vivo (81), sug-
gesting that VEGF contributes to angiogenesis and
tumor progression also in AGCTs.
Treatment
During the last decade, our understanding of the
molecular pathogenesis of AGCTs has significantly
improved, whereas the developments of chemothera-
peutic regimens and especially targeted therapies have
remained modest. Thus, optimal primary surgery still
has kept its position as the most determining factor in
the treatment of both primary and relapsed AGCTs.
Surgery
In the treatment of primary AGCT, complete surgical
removal of the tumor, uterus, ovaries and fallopian
tubes, complemented with staging procedures (peri-
toneal washings, biopsies, and infracolic omentectomy)
form the golden standard (82). Pelvic and para-aortic
lymphadenectomy (i.e. surgical removal of lymph
nodes) are generally not recommended (82), and only
bulky or suspicious nodes should be removed. Surgery
can be performed in either laparotomy or laparoscopy
(33% of primary operations), while the laparoscopic
approach has been reported safe and associates with
less morbidity (83). In patients presenting with a local
disease (stage Ia) and wishing to preserve their fertility,
a conservative surgery sparing the normal contralateral
ovary and uterus can be performed. In these cases,
however, a careful staging procedure coupled with
endometrial sampling should be carried out to exclude
metastatic disease and/or concurrent endometrial
pathology. It is noteworthy, that there is no consensus
of whether radical surgery should be performed when
these patients have completed their childbearing or
when they reach menopause.
The relapsed disease is often multifocal, and com-
plicated by the fact that there is no standard surgical
approach or treatment protocol. The most common
site of relapse is the pelvis, but abdominal and peri-
toneal disease, as well as retroperitoneal metastases
can occur (5,83,84). Similar to primary disease, the
treatment of relapsed disease should aim for optimal
surgical debulking whenever possible (5,82,84). This is
crucial since the presence of postoperative residual
tumor has been shown to be an important prognostic
factor for both subsequent tumor relapse, and survival
(8,13). Further, patients with recurrent disease are
likely to benefit even from repeated surgical
approaches if optimal debulking can be achieved (5).
And indeed, according to two retrospective reports, an
optimal debulking with no macroscopic residual tumor
can be achieved in the majority of the patients in sec-
ondary surgery (83,84). However, multivisceral surgical
procedures may be needed to achieve optimal debulk-
ing, which associate with a significantly increased risk
of postoperative complications. However, a prolonged
disease-free survival was reported in a small patient
series regardless of the additional risks associated with
repeated and extensive surgical procedures (85).
Chemotherapy
Surgery forms the cornerstone of treatment in most
AGCTs that are diagnosed at an early stage, and no
medical therapies are usually considered. Advanced
and/or inoperable chemotherapy is offered, although
its efficacy and prognostic significance largely remain
unsure. The role of adjuvant chemotherapy in AGCTs
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is also obscure; reasonably high response rates have
been reported (86,87), however ,adjuvant chemother-
apy does not seem to significantly affect patient out-
comes (8). Traditionally, platinum-based combination
therapies have been utilized as the primary thera-
peutic option (88,89). Response rates for the most
common combination of bleomycin, etoposide and cis-
platin vary from 37% to 83% in older studies (88,90),
but in the most recent series the responses are only
moderate, reaching 22–35% (9,89). It must be noted,
however, that the current evidence is based on mostly
retrospective studies on non-validated AGCT cohorts,
presenting as a potential confounder when evaluating
these responses. Combination chemotherapy with
paclitaxel and carboplatin has also been used, provid-
ing with the same efficacy albeit less toxicity com-
pared with bleomycin, etoposide and cisplatin (90).
Interestingly, The Gynecologic Oncology Group is cur-
rently running a randomized trial comparing these two
combination treatments, hopefully providing a clarifi-
cation to the choice of optimal chemotherapeutic
regimen.
Hormonal and targeted treatments
AGCTs are known to express steroid hormone recep-
tors and produce estradiol. Therefore, hormonal treat-
ments have been empirically utilized in AGCTs, mostly
as a last resort in patients with non-operable AGCTs.
Hormonal therapies have also been considered if the
patient has not tolerated or the tumor has not
responded to conventional chemotherapy. The treat-
ment modalities have included progestins, gonado-
trophin releasing hormone agonist, selective estrogen
receptor modulators, and aromatase inhibition. In a
systematic review including 19 studies describing the
response to hormonal therapy, the pooled objective
response rate was as high as 71% (91). However, in a
retrospective analysis of 22 patients from a single insti-
tute, the objective response rate was unexpectedly
low (18%) (70). Similarly, Wilson et al. reported a
response rate of 14% to aromatase inhibitors in
patients with relapsed stage I AGCTs (9). It is note-
worthy, that no randomized trials have been per-
formed regarding hormonal treatments, and the
current literature consists only relatively small retro-
spective series and case reports. In addition, none of
these studies have been performed in FOXL2 molecu-
larly defined cohorts, and there is potential bias from
patient selection and response evaluation for the
benefit of these treatments. Thus, the true efficacy of
hormonal therapy in AGCTs remains unknown. Further,
the biological principles and mechanisms of action of
hormonal treatments in AGCTs are unclear (see above).
After the hormonal pathogenesis is clarified in more
detail, and there is supportive evidence from a
randomized trial, hormonal therapy may be an option
in the treatment of AGCTs.
The only targeted therapy with proven efficacy in
advanced ovarian cancer is angiogenesis inhibition,
most importantly with humanized monoclonal VEGF
antibody bevacizumab (92). In AGCTs, bevacizumab
was considered active in a phase II clinical trial on
advanced AGCTs (93). Thus, bevacizumab may be a
viable option in advanced AGCTs.
Follow-up and timing of treatment
Follow-up of AGCT patients consists of standard gyne-
cological examinations with ultrasound and blood
samples for at least 3–5 years (82,94). The roles of
gynecological exam and transvaginal ultrasound in
clinical follow-up are unclear as their sensitivity to
detect relapses outside the pelvis are limited. Thus,
serum markers are commonly utilized as a part of the
standard follow-up scheme. Serum inhibin B has the
strongest evidence as a tumor marker for AGCTs (95).
Granulosa cells of developing follicles produce inhibin
B and its serum levels are high in the early follicular
phase (96). After menopause, circulating inhibin B con-
centrations are undetectable. In AGCT patients, inhibin
B is superior to inhibin A, with reported sensitivities
between 88-100% for inhibin B, and 67-77% for inhibin
A, respectively (97). AMH has also been validated as a
marker for AGCT, and both AMH and inhibin B are
equally sensitive (92 and 93%) and specific (82 and
83%) in this disease (75). In addition, both markers are
also elevated in relapsed disease and their levels posi-
tively correlate with disease burden (75). The combin-
ation of AMH and inhibin B seems to be superior to
inhibin B alone in detecting macroscopic disease. In
premenopausal patients, there are no established cut-
off levels for AMH or inhibin B, and new studies are
needed to establish the reference values for AMH and
inhibin B. Currently, the levels should be evaluated
individually, and patients with rising AMH vaifact that
functional granulosa cells are the only source of AMH
and inhibin B. It is thus recommended that both
markers should be measured at diagnosis, and subse-
quently one positive marker, either AMH or inhibin B,
may be monitored during follow-up (75).
AMH and inhibin B levels have been reported to
rise several months or even years before the onset of
clinical symptoms of the relapse, the lead-times have
been reported 0.9–2.8 years for inhibin B, and 3.4
years for AMH (75,97). The clinical significance of the
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early marker rise in regards to patient survival and
morbidity can only be speculated upon. To date, there
is no evidence supporting the treatment of asymptom-
atic ovarian cancer patients (98). However, early detec-
tion of a relapse by close monitoring with serum
markers may result into a more optimal surgical man-
agement of the relapse (99).
Treatment challenges and future perspectives
The key challenges and suggested solutions in the
management of AGCT patients are summarized in
Table 2. In support of recent evidence, accurate diag-
nostics is the cornerstone in the treatment of AGCT
patients, and expert pathological review in conjunction
with FOXL2 mutation testing should become the
standard of care for patients with AGCT.
The surgical treatment of AGCT should aim for opti-
mal cytoreduction, coupled with complete staging,
and the centralization of treatment of these patients is
essential to ensure the quality and resources of the
treatment. The prognostic difference between stage Ia
and Ic patients is clinically relevant (17), and special
attention should be paid on the surgical management
of these patients. In stage Ia patients, rigorous efforts
should be concentrated at preventing tumor rupture
and dissemination of the tumor cells onto the abdom-
inal cavity during operation. Upon laparoscopic
approach, this requires a trained endoscopic surgeon,
and the use of special instruments to safely remove
the tumor. This underlines the importance of the pre-
operative evaluation, and the referral of these patients
to a gynecological oncologist for primary care.
Further, a major clinical challenge is to identify
patients at risk of recurrence. In addition to tumor
stage, the current literature offers no consistent prog-
nostic factors. Therefore, further studies in validated
cohorts are needed to identify AGCT patients at
increased risk of relapse, and to find out whether they
would benefit from adjuvant treatments or mainten-
ance therapy to prevent recurrence
A demanding clinical challenge also arises from the
treatment of relapsed or advanced molecularly defined
AGCTs. In these cases, platinum-based adjuvant
chemotherapy is commonly utilized. However, it is
known that platinum-based therapies most efficiently
target rapidly dividing cells with DNA repair defects.
Further, the rationale of using platinum in AGCTs is
based on small, mostly retrospective series, and more
importantly from cohorts with no diagnostic validation
(89). Recent studies have shown that the patients with
the most aggressive AGCTs are more likely to have a
different tumor type and are not AGCTs (11), causing
potential bias when evaluating the treatment
responses from historical cohorts. Notably, AGCTs
seem to retain the pathognomonic FOXL2 mutation,
and their original gene expression profile and chromo-
somal architecture even after multiple relapses. The
clinical picture of AGCT with slow growth, indolent
prognosis supports the use of conservative approach
to adjuvant therapy with conventional chemothera-
peutics so as to avoid toxicity. Considering the patho-
genesis and stable karyotype of FOXL2 molecularly
defined AGCTs, new approaches are needed to find
new, effective treatment options for patients with
relapsed and inoperable AGCT.
The relative rarity of the tumor and its prolonged
disease course make studies on new drugs and combi-
nations in prospective clinical trials difficult and time-
consuming. Large international clinical trials with
molecularly defined AGCT cohorts are needed to
validate new treatment strategies for patients with
high-risk early-stage and advanced AGCTs. The estab-
lishment of new effective treatments should also rely
Table 2. Challenges and suggested solutions in the management of AGCT patients.
AGCT charactistic Clinical challenge Suggested solution and objects for future studies
Importance of optimal primary surgical treat-
ment on progonsis
Surprise AGCT diagnosis or tumor rupture at
operation leading to higher stage, typically
Ic, and increased risk of relapse.
Accurate preoperative diagnostics with e.g. circu-
lating tumor markers (AMH, inhibin B), and the
referral of AGCT patients to a gynecological
oncologist for primary treatment.
Significant variation in outcomes, unpredict-
able clnical course
Unequivocal histological diagnosis, and the lack
of prognostic indicators to identify patients
at risk of relapse
Diagnosis verification with FOXL2 402C->G muta-
tion testing, preferably with a sensitive method
such as allelic discrimination assay.
Identification of prognostic markers among
molecularly validated AGCTs.
Long latency to relapse How, and how long to follow-up the patients Use of accurate serum markers (AMH, inhibinB),
identification of “high risk” patients with e.g.
ctDNA
Relapse in 30% of the early stage patients Which patients are in need of prolonged
follow-up
Identification of patients at high risk of relapse
that most likely benefit from adjuvant therapy
and possibly maintenance therapy to prevent
relapse.
Increased (50%) mortality to relapsed AGCT How to optimally treat relapsed AGCT, what
chemotherapeutics are effective.
New studies on chemotherapy and targeted treat-
ments, as well as hormonal therapy.
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on the deeper understanding of the pathogenesis of
AGCTs.
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